NEW YORK (GenomeWeb News) – OriGene Technologies announced that it has received a contract from the National Cancer Institute to develop high affinity anti-peptide antibodies for SISCAPA assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.